Semaglutide is a long-acting GLP-1 receptor agonist available as a once-weekly injection or a daily oral tablet. It is highly effective in lowering blood sugar levels in type 2 diabetes and is also widely recognised for promoting significant weight loss and reducing cardiovascular risks.

Liraglutide is a GLP-1 receptor agonist administered by daily injection. It is used to improve blood sugar control in type 2 diabetes and, at a higher dose, for chronic weight management. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and heart disease.